High radial force with mínimum recoil to be able to treat BTK lesions.
Specifically designed for homogeneous arterial coverage.
TransferWise, the iVascular proprietary technology that provides a homogenous drug elution that translates into lower rates of restenosis and inflammation score.
Our fluoro-acrylate polymer provides an early endothelialization and creates a thromboresistant layer.
Angiolite BTK has demonstrated its safety and efficacy in the following clinical trial:
ANGIOLITE BTK Trial
Prospective, real-life trial in BTK lesions.
at 6 months.